Comparison of the antiandrogenic/androgenic activities of flutamide, cyproterone acetate and megestrol acetate

@article{Poyet1985ComparisonOT,
  title={Comparison of the antiandrogenic/androgenic activities of flutamide, cyproterone acetate and megestrol acetate},
  author={Patrick Poyet and Fernand Labrie},
  journal={Molecular and Cellular Endocrinology},
  year={1985},
  volume={42},
  pages={283-288}
}
  • P. Poyet, F. Labrie
  • Published 1 October 1985
  • Medicine, Chemistry
  • Molecular and Cellular Endocrinology
Flutamide is approximately 2-fold more potent than cyproterone acetate in reversing the stimulatory effect of dihydrotestosterone (DHT) on ventral prostate weight. Even at the highest dose of cyproterone acetate, prostate weight remains 40% above control while flutamide completely reverses the stimulatory action of DHT, thus suggesting some partial androgenic activity of cyproterone acetate. Megestrol acetate, on the other hand, is devoid of any antiandrogenic activity and it even increases the… 
Effect of cyproterone acetate in comparison to flutamide and megestrol acetate on the ventral prostate, seminal vesicle, and adrenal glands of adult male rats
TLDR
A critical review of all available data on the antiandrogenic, glucocorticoidlike, and possible paradoxical androgenlike activities of CPA in different animal experiments has no important bearing on the clinical effectiveness of C PA in the treatment of prostatic cancer.
Analysis of the androgenic activity of synthetic "progestins" currently used for the treatment of prostate cancer.
TLDR
The present data show that MPA is a highly potent androgen while megestrol acetate, CMA, CPA and spironolactone have lower but significant androgenic activity on all the parameters measured.
Effects of flutamide, a pure antiandrogen, on endocrine parameters, in the adult female rat.
TLDR
The present data show that treatment of intact adult female rats with the pure antiandrogen Flutamide has no effect on the estrous cycle, with no significant change in the plasma concentration of the most important estrogenic compound in the rat, namely, 17 beta-estradiol.
Mechanism of action and pure antiandrogenic properties of flutamide
TLDR
Though castration reduces intraprostatic dihydrotestosterone (DHT) to undetectable levels in the rat and guinea pig, the concentration remains at about 50% of the value found in intact men after castration, thus indicating an important contribution of the adrenals to DHT in the human prostate, a finding that requires the addition of an antiandrogen to block the action of this important amount of DHT remaining afterCastration.
Rat prostatic weight regression in reaction to ketoconazole, cyproterone acetate, and RU 23908 as adjuncts to a depot formulation of gonadotropin-releasing hormone analogue.
TLDR
The effects of the s.c. administration of a depot formulation of the luteinizing hormone-releasing hormone (LHRH) analogue Zoladex were studied in normal male rats to investigate whether these antiandrogens might prevent the LHRH-A-induced initial increase in these parameters.
Characteristics of flutamide action on prostatic and testicular functions in the rat.
TLDR
The present data clearly show that combined treatment with an LHRH agonist and a pure antiandrogen is highly effective in inhibiting, not only prostatic growth, but also two androgen-sensitive parameters of prostatic activity.
Comparative effects of chronic administration of the non-steroidal antiandrogens flutamide and Casodex on the reproductive system of the adult male rat.
TLDR
It is concluded, that Casodex, in contrast to flutamide, is a peripherally selective antiandrogen, and therefore this anti androgen might be useful clinically for selectively blocking androgen actions in the accessory sex glands.
Daily dosing with flutamide or Casodex exerts maximal antiandrogenic activity.
TLDR
Casodex is about three times less potent than flutamide on the well-recognized parameters of androgen responsiveness in the rat, namely prostate and seminal vesicle weights, which should be helpful in determining the choice of an appropriate dose of Casodex for the treatment of prostate cancer.
Antiandrogenic activity and endocrinological profile of a novel antiandrogen, TZP-4238, in the rat.
TLDR
It is suggested that TZP-4238 exerts an antiandrogenic effect on the prostate without any compensatory change in the serum concentration of luteinizing hormone or testosterone in rats, and it is a useful drug for the treatment of androgen-dependent diseases such as prostatic hypertrophy and prostatic cancer.
Pharmacology of antiandrogens and value of combining androgen suppression with antiandrogen therapy.
TLDR
Nilutamide counteracts the trophic effect of adrenal androgens left intact by castration, which can only be suppressed by treatments that also suppress corticoid synthesis, and has been shown in the rat treated with buserelin.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 17 REFERENCES
Effect of megestrol acetate (Megace) on steroid metabolism and steroid-protein binding in the human prostate.
Megestrol acetate (Megace), an antiandrogen, was administered in a dosage of 80 mg daily to 6 patients with benign prostatic hypertrophy (BPH) for 4 to 25 days prior to transurethral resection of the
Biological studies on an anti-androgen (SH 714).
TLDR
This compound is strongly anti-androgenic in testosterone-stimulated, orchiectomized rats and in intact male rats when administered either subcutaneously or orally, and at high doses, possesses anti-gonadotropin activity.
Anti-androgens do not alter androgen-dependent characteristics of acid phosphatase in the rat ventral prostate
TLDR
The results suggest that these anti-androgens affect only some of the androgen-dependent functions of the prostate.
A biological profile of a nonsteroidal antiandrogen, SCH 13521 (4'-nitro-3'trifluoromethylisobutyranilide).
TLDR
A comparative study in castrated rats revealed that Sch 13521 was equipotent to cyproterone acetate (CPA) as an antiandrogen, but unlike CPA, it did not effect parturition time.
Medical castration of males with megestrol acetate and small doses of diethylstilbestrol.
TLDR
It is concluded that the use of 0.1 mg DES with a minimum of 40 mg/day MA results in medical castration with sustained suppression of plasma testosterone, and this combined therapy should be further explored as a possible initial treatment of choice for advanced prostate cancer.
Cyproteroneacetate and ACTH adrenal function.
TLDR
In rats, adrenal atrophy and severe impairment of ACTH and corticosterone responses to stress are induced by a 10-day treatment with cyproteroneacetate, and in children treated for precocious puberty, severely impaired ACTH adrenal function is revealed.
New hormonal therapy in prostatic carcinoma: combined treatment with an LHRH agonist and an antiandrogen.
TLDR
It is indicated that a combined hormonal therapy which neutralizes all androgenic influences on peripheral tissues is of potential benefit in prostatic cancer and should minimize the development of metastases and androgen-resistant cell clones.
Selective effect of androgens on LH and FSH release in anterior pituitary cells in culture.
TLDR
The finding that total LH remained constant after incubation with T or DHT clearly indicates that the inhibition of the LH response to LHRH is really due to changes in the sensitivity of the releasing mechanisms in the LH-secreting cells.
Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate
TLDR
It is demonstrated that a marked rise in acid phosphatase in serum is associated with the appearance or spread of roentgenologically demonstrable skeletal metastases and implies dissemination of the primary tumor and thus is of unfavorable prognostic significance.
Cardiovascular complications in the treatment of prostatic carcinoma.
TLDR
It is recommended that stilboestrol and estramustine phosphate should not be used in the presence of cardiovascular disease and that the primary form of treatment in prostatic carcinoma should be bilateral orchiectomy, especially in patients with localised disease.
...
1
2
...